PL2203170T3 - Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny - Google Patents

Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny

Info

Publication number
PL2203170T3
PL2203170T3 PL08833688T PL08833688T PL2203170T3 PL 2203170 T3 PL2203170 T3 PL 2203170T3 PL 08833688 T PL08833688 T PL 08833688T PL 08833688 T PL08833688 T PL 08833688T PL 2203170 T3 PL2203170 T3 PL 2203170T3
Authority
PL
Poland
Prior art keywords
alfuzosine
adrenergic
therapeutic uses
novel therapeutic
novel
Prior art date
Application number
PL08833688T
Other languages
English (en)
Inventor
Pierangelo Geppetti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PL2203170T3 publication Critical patent/PL2203170T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08833688T 2007-09-26 2008-09-24 Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny PL2203170T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97532407P 2007-09-26 2007-09-26
EP07291148A EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
EP08833688A EP2203170B1 (en) 2007-09-26 2008-09-24 NOVEL THERAPEUTIC USES OF ADRENERGIC ALFUZOsINE
PCT/IB2008/003126 WO2009040671A1 (en) 2007-09-26 2008-09-24 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists

Publications (1)

Publication Number Publication Date
PL2203170T3 true PL2203170T3 (pl) 2012-02-29

Family

ID=38754714

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08833688T PL2203170T3 (pl) 2007-09-26 2008-09-24 Nowe zastosowania terapeutyczne adrenergicznej alfuzosyny

Country Status (15)

Country Link
US (1) US8492396B2 (pl)
EP (2) EP2042179A1 (pl)
JP (1) JP5478495B2 (pl)
AR (1) AR068825A1 (pl)
AT (1) ATE524185T1 (pl)
CY (1) CY1112203T1 (pl)
DK (1) DK2203170T3 (pl)
ES (1) ES2373354T3 (pl)
HR (1) HRP20110919T1 (pl)
ME (1) ME01259B (pl)
PL (1) PL2203170T3 (pl)
PT (1) PT2203170E (pl)
RS (1) RS52069B (pl)
SI (1) SI2203170T1 (pl)
WO (1) WO2009040671A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020015377A1 (zh) * 2018-07-18 2020-01-23 温州医科大学 一种治疗近视的方法及制备药物的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
IL133913A0 (en) * 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
DK1385548T3 (da) * 2001-01-26 2007-09-10 Schering Corp Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
DE60234318D1 (de) * 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
KR20100036390A (ko) * 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20050261344A1 (en) * 2002-08-14 2005-11-24 Jones Charles R Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
EP1644369A2 (en) * 2003-07-02 2006-04-12 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Also Published As

Publication number Publication date
HRP20110919T1 (hr) 2012-01-31
US20110009436A1 (en) 2011-01-13
JP2010540511A (ja) 2010-12-24
ME01259B (me) 2013-06-20
ES2373354T3 (es) 2012-02-02
DK2203170T3 (da) 2012-01-16
RS52069B (sr) 2012-06-30
WO2009040671A1 (en) 2009-04-02
EP2203170B1 (en) 2011-09-14
PT2203170E (pt) 2011-12-27
SI2203170T1 (sl) 2012-01-31
CY1112203T1 (el) 2015-12-09
WO2009040671A4 (en) 2009-05-28
EP2042179A1 (en) 2009-04-01
US8492396B2 (en) 2013-07-23
JP5478495B2 (ja) 2014-04-23
AR068825A1 (es) 2009-12-09
ATE524185T1 (de) 2011-09-15
EP2203170A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
PT2954932T (pt) Utilização terapêutica de diaminofenotiazinas
GB0813087D0 (en) Therapeutic compounds
GB0716532D0 (en) Therapeutic compounds
ZA200906187B (en) Reducing side effects of tramadol
ZA201003941B (en) Use of rr/sr-ractopamine
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
GB0724340D0 (en) Novel Therapeutic Agents
IL208236A0 (en) Use of cathepsin c
ZA201000225B (en) Treatment of depression
ZA200905468B (en) Therapeutical uses of eslicarbazepine
IL199765A0 (en) Use of tocopherol
GB0723100D0 (en) Treatment of HFnEF
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
GB201114396D0 (en) Location of basesation
GB0702862D0 (en) Therapeutic compounds
SI2203170T1 (sl) Nove terapevtske uporabe adrenergičnega alfuzosina
GB0708188D0 (en) Therapeutic compounds
GB0708186D0 (en) Therapeutic compounds
GB0705204D0 (en) Uses of (S)-clenbuterol
PL383760A1 (pl) Nowe zastosowanie undekan-2-olu
PL383759A1 (pl) Nowe zastosowanie undekan-2-olu
PL383758A1 (pl) Nowe zastosowanie undekan-2-onu
ZA200904356B (en) Use of tocopherol